Last reviewed · How we verify
International Extranodal Lymphoma Study Group (IELSG) — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| high dose cytarabine | high dose cytarabine | phase 3 | Nucleoside analog antimetabolite | DNA synthesis (cytidine analog) | Oncology | |
| rituximab+chlorambucil | rituximab+chlorambucil | phase 3 | Monoclonal antibody + alkylating agent | CD20 | Oncology | |
| chlorambucil (drug) | chlorambucil (drug) | phase 3 | Alkylating agent | DNA | Oncology |
Therapeutic area mix
- Oncology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- University of California, San Diego · 2 shared drug classes
- Asahi Kasei Pharma Corporation · 1 shared drug class
- Celyad Oncology SA · 1 shared drug class
- Astellas Pharma China, Inc. · 1 shared drug class
- Baxter · 1 shared drug class
- BeBetter Med Inc · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Alberta Health services · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for International Extranodal Lymphoma Study Group (IELSG):
- International Extranodal Lymphoma Study Group (IELSG) pipeline updates — RSS
- International Extranodal Lymphoma Study Group (IELSG) pipeline updates — Atom
- International Extranodal Lymphoma Study Group (IELSG) pipeline updates — JSON
Cite this brief
Drug Landscape (2026). International Extranodal Lymphoma Study Group (IELSG) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/international-extranodal-lymphoma-study-group-ielsg. Accessed 2026-05-16.